Next Article in Journal
The Rescue and Characterization of Recombinant, Microcephaly-Associated Zika Viruses as Single-Round Infectious Particles
Previous Article in Journal
Molecular Piracy: Redirection of Bacteriophage Capsid Assembly by Mobile Genetic Elements
Open AccessCommunication

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports

1
Laboratório de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365–Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil
2
Serviço de Hepatologia, Universidade Federal do Rio de Janeiro, Rua Professor Paulo Rodolpho Rocco, 255, Cidade Universitária, 21044-020 Rio de Janeiro, RJ, Brazil
3
Hospital Quinta D’Or. Rua Almirante Baltazar, 435, São Cristóvão, 20941-150 Rio de Janeiro, RJ, Brazil
4
Instituto Nacional de Infectologia Evandro Chagas, INI/FIOCRUZ, Avenida Brasil, 4365-Manguinhos, 21040-360 Rio de Janeiro, RJ, Brazil
*
Authors to whom correspondence should be addressed.
Viruses 2019, 11(11), 1004; https://doi.org/10.3390/v11111004
Received: 17 July 2019 / Revised: 28 August 2019 / Accepted: 5 September 2019 / Published: 31 October 2019
(This article belongs to the Section Antivirals & Vaccines)
In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therapy) might limit the achievement of sustained virologic response (SVR). Here, we described two case reports in which the occurrence of HCV NS5A mutations A30K (subtype 3a) and Y93N (subtype 1a) might have influenced daclatasvir (DCV)/sofosbuvir (SOF) combined therapy non-response. Despite high response rates for DAA combined therapies in Brazil, these case reports stated the importance of an investigation about how to manage a DAA treatment failure since a combination of factors, especially the occurrence of resistance substitutions, could impact a rescue therapy with new available antivirals in clinical routine. View Full-Text
Keywords: hepatitis C virus (HCV); DAA; resistance hepatitis C virus (HCV); DAA; resistance
Show Figures

Figure 1

MDPI and ACS Style

Costa, V.D.; Pellegrini, P.; Rotman, V.; Pittella, A.M.; Nunes, E.P.; Lago, B.V.; Lampe, E.; Mello, F.C.A. Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports. Viruses 2019, 11, 1004.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop